PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells
about
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survivalCostimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic targetImmune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?Adoptive immunotherapy against ovarian cancerPD-1/PD-L1 blockade in cancer treatment: perspectives and issuesAdaptive Immune Resistance: How Cancer Protects from Immune AttackControl of CD8 T-Cell Infiltration into Tumors by Vasculature and MicroenvironmentThe programmed death-1 immune-suppressive pathway: barrier to antitumor immunityOvercoming T cell exhaustion in infection and cancerCancer immunotherapyPrognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis.Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaThe blockade of immune checkpoints in cancer immunotherapyThe concept of immune surveillance against tumors. The first theoriesPD-L1 and Survival in Solid Tumors: A Meta-AnalysisAnti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potentialFacilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 BlockadeThe role of the PD-1 pathway in autoimmunity and peripheral toleranceVISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responsesNew aspects of an old drug--diclofenac targets MYC and glucose metabolism in tumor cellsPhase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesImmunosuppressive strategies that are mediated by tumor cellsControl of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cellsMesenchymal stem cells repress Th17 molecular program through the PD-1 pathway.Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data.Engineering higher affinity T cell receptors using a T cell display system.B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells.Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy.The use of immunotherapy in the treatment of melanomaAnti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy.Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.Checkpoint inhibitors in hematological malignanciesCD40-activated B cells induce anti-tumor immunity in vivo.Gene expression profiling of murine T-cell lymphoblastic lymphoma identifies deregulation of S-phase initiating genes.Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance.PD-1, gender, and autoimmunity.VISTA Regulates the Development of Protective Antitumor Immunity.PD-L1 is increased in the spinal cord and infiltrating lymphocytes in experimental allergic encephalomyelitisMyxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity
P2860
Q24550945-850C6254-0CC3-4531-A678-A11730C55162Q24559442-EFC5E0B9-F992-4609-A9C4-08E0283AB539Q26740601-F461D199-BDDC-403D-806C-7EBBAE974CCBQ26748905-A699F97A-8F85-414C-91C7-9332FA556B52Q26768641-E042DA59-D2D9-418D-A5AE-0B7DD25A24D8Q26798448-E7BF3DEA-2604-46AD-8E13-B90843BD938EQ26799117-D28A91FA-6691-44A4-8CB5-93F0D9A9E353Q26829847-17BFE00A-D032-477C-8F70-607F6EE782FBQ26829885-395A4568-7D58-4FD5-B382-428DACC6BA6BQ27026870-899286D5-5AE6-4167-9F2F-80E19EBBB10EQ27853291-083ED5B6-3CC5-4085-91AA-9D97136D6600Q27860650-AE2B38A3-97A2-4EAF-9067-D749DF644CADQ27860852-9F26C206-F641-4673-B5BC-5703810E88A7Q28073937-599F7EC1-0563-48E3-BDC3-99B8AA51790FQ28084090-5304F9AC-B952-44BD-86FB-A3C11AB30F4AQ28084942-F057873D-0546-4C65-A564-2B0AB58569FFQ28119095-8133B69B-C43A-4A41-A39B-07AEF05F19D1Q28304161-C2D2DC4B-606D-46AF-8B96-5F31DC392C40Q28504888-8278457E-0402-4FFA-A3FA-B99288F8E257Q28534587-1AE5811D-E0C9-4CD7-8558-9B2549319897Q29620051-4377CAE5-4713-4743-BA22-30499D34032EQ29636247-A49B4C59-3202-471F-8C2D-B658A4E61596Q30430481-6FF850AB-16D7-4CD3-B5F6-83D5A66DEB3FQ31101562-4FB35BB1-B350-4503-B2E0-24226855F28EQ31137039-85E460C7-FC74-434B-864A-3B4AD62B19A6Q33375887-B7462AB9-26F0-4EEE-AD99-A699D57A4F3EQ33574520-9AE92D74-84E4-4EB1-9B05-7913346F283AQ33586463-858E1001-5692-4060-AB8B-CA73888BD79BQ33593858-9F7ABB47-EE05-4F97-B8D5-16ECF4FA648CQ33606111-9A7B20B5-2BA1-4C30-B802-420BCFACA868Q33606150-8CDF7856-7F83-4584-82B3-9EA6E6B7D7FBQ33638083-D94E8C38-12EA-453D-A49C-54ADE49C0F54Q33651495-CFF0FC7D-1F14-4F34-9044-248801C1DCACQ33709425-47F82174-E534-421E-B29B-642EBEB7F9D1Q33756543-22538B77-9176-43A5-9905-E3556B4FD3FDQ33822831-69039190-F835-495B-9E4B-B7356984C03CQ33910421-4BE717B0-0A80-422C-AFA1-A5616CDF853BQ33978040-779EB853-5833-47DD-B7C5-541841355178Q34094680-67CD2806-74DC-4C57-B254-6339B40424C0Q34351517-77B0DB37-BFED-49C3-82DA-051A3658816E
P2860
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
PD-L1/B7H-1 inhibits the effec ...... (TCR) transgenic CD8+ T cells
@ast
PD-L1/B7H-1 inhibits the effec ...... (TCR) transgenic CD8+ T cells
@en
PD-L1/B7H-1 inhibits the effec ...... (TCR) transgenic CD8+ T cells
@nl
type
label
PD-L1/B7H-1 inhibits the effec ...... (TCR) transgenic CD8+ T cells
@ast
PD-L1/B7H-1 inhibits the effec ...... (TCR) transgenic CD8+ T cells
@en
PD-L1/B7H-1 inhibits the effec ...... (TCR) transgenic CD8+ T cells
@nl
prefLabel
PD-L1/B7H-1 inhibits the effec ...... (TCR) transgenic CD8+ T cells
@ast
PD-L1/B7H-1 inhibits the effec ...... (TCR) transgenic CD8+ T cells
@en
PD-L1/B7H-1 inhibits the effec ...... (TCR) transgenic CD8+ T cells
@nl
P2093
P3181
P1433
P1476
PD-L1/B7H-1 inhibits the effec ...... (TCR) transgenic CD8+ T cells
@en
P2093
Amy C Peterson
Christian Blank
Mike Spiotto
Thomas F Gajewski
Yoshiko Iwai
P304
P3181
P356
10.1158/0008-5472.CAN-03-3259
P407
P50
P577
2004-02-01T00:00:00Z